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It is nothing new to resort to psychoactive substances in the absence of any 
pathology or subclinical condition in order to enhance or improve one's 
performance. After all , various substances have been used in sport, study, 
and work activities and even hallucinogenic effects have been noted. 
This matter has come up again after increasing dispersion of anti-
depression products among those who are neither depressed nor dysthymic 
b· • su ~ects . 
Studies in neurochemistry and neurophysiology have highlighted 
that the brain tone depends on the production of a specific substance, 
serotonin , which is, after some time, removed from blood circulation 
(reuptake) by specific nervous receptors, so as to extinguish its effects. A 
rapid drop of this substance is responsible for certain kinds of depression, 
anxiety, suicidal tendencies, chronic pain, compulsive eating, 
sleeplessness, irritability!, and aggressive behavior.2 
For this reason, medications that inhibit serotonin reuptake from 
blood circulation have been produced. These medications maintain the 
high level of serotonin which means a good mood (euthymia) , sound sleep, 
appetite satiation, and pain relief. Some individuals who were committed 
to spiritual meditation were initially reluctant to take a drug because it 
might "contaminate their mind"; they also did not agree with the idea that 
the "dark of the soul" - depression - should be treated pharmacologically. 
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However, they report that they have found not only relief but spiritual 
growth as a result of using these products.3 
Brain serotonin levels, therefore, apparently are a part of what 
determines several aspects of human personality - especially the affective 
and motivational ones. This was confirmed through examination of 
patients with a history of impulsively violent behavior (e.g., arsonists, 
criminals, people who die by violent suicide). They showed low brain 
serotonin levels. Pharmacological interventions that increase cerebral 
serotorun levels can lead to a reduction of hostility and violent outbursts in 
aggressive psychiatric patients. 
The most well-known selective serotonin reuptake inhibitor is 
Prozac (the commercial name of f1uoxetine) , which was put on the market 
as an antidepressant in 1987. Up to 1994 it had been used by nearly 11 
million people, more than half of them in the United States.4 
Among the many reasons that patients use Prozac are the relative 
absence of side effects (limited to nausea, diarrhea, and sexual dysfunction) 
compared to other tricyclics also used as antidepressants; and its fast action. In 
fact, the effects sought through use ofProzac appear after only two to three 
weeks, whereas psychotherapy requires something like two to three years. 
One could ask: Why spend the time, money, and energy to undergo 
psychotherapy if the same result, indeed better results, can be reached by 
simply and autonomously taking a pill which has no side effects? 
Deontological and Ethical Dilemmas 
From an ethical and deontological point of view, the administration 
of a selective serotonin reuptake inhibitor in subjects showing symptoms of 
clinical depression seems to cOlTespond completely to the therapeutic 
principle, although an utter replacement of psychotherapy irfvolves a pure 
biologist view of psychiatric diseases. Thus, origins of mental disease 
would be explained through anatomical-clinical alterations of the brain, 
rather than through traumas that eventually are present in memory (as a 
matter of fact, such traumas may represent a determining factor in some 
kinds of mental disease). 
The case of healthy people who ask for Prozac in order to enhance 
their mood and work performance is quite a different matter. There are 
obviously different opinions about that, the disagreement being a 
consequence of one's idea of nature and the human condition.5 
There are at least two possible perspectives. The first, which could 
be defined briefly as the "SOITOW perspective," assumes that life is not 
characterized by continuous happiness, contentment, and well-being, 
rather by a struggle filled with pain, disappointment, grief, and mourning. 
Therefore, SOITOW must be considered a privileged state that we do not 
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have to eliminate. The second assumes that life can and should be as 
fulfilling as possible. Therefore, pain, anxiety, and sadness are symptoms 
that can and should be alleviated by whatever means possible. 
As a consequence, the first perspective maintains that Prozac would 
rob life of a fundamental aspect, namely the possibility of facing 
difficulties, pain, and anxiety. These experiences are considered typical of 
the human condition, therefore should be embraced rather than deleted by 
psychoactive substances. This has been called "pharmacological 
Calvinism", which implies that any quick cure by a chemical substance-
without pathologies - should be considered suspect, and even 
dehumanizing. 
It would be suspect because these medications reduce the demand 
for psychotherapy and it would be dehumanizing because they replace the 
interpersonal relation between patient and therapist with a pill. Perhaps, 
the basic fear is also that these medications would be trivialized and used 
for hedonistic reasons. 
The second perspective starts from the assumption that suffering in 
itself does not engender human growth and self-transformation. On the 
contrary, permitting and encouraging suffering is considered sadistic, since 
medications like Prozac can prevent suffering, may allow us to be more 
creative and alive, and can even change our behavior and our sense of 
constraint. 
Some years ago, P. Kramer published a book, an immediate best-
seller, with the evocative title of Listening to Prozac,6 concerning the 
replacement of psychotherapy with psychopharmacology in depressive 
pathologies. According to Kramer, the difference of opinion about these 
drugs was a consequence of the different ideas of mental disease. Does the 
problem have a biological or cultural basis? For KraPler, mental disease 
has biological origins only; in fact, Prozac restores patients - even the 
healthy ones - to their apparently original and biologically determined 
state, freeing them from the inhibitions (constraints) of their life 
experiences and family nurturance (influence). It almost seems as if 
patients regain their "true selves." 
B. Knutson et aI. , who also agree with the biological view of mental 
disease, studied the effects of selective interventions on cerebral 
functioning.7 They assigned paroxetin - another potent selective serotonin 
reuptake inhibitor - to 51 psychophysically healthy patients, establishing 
that such medications may modulate some personality charactelistics also in 
normal individuals, particularly hostile behavior, as against placebo control 
subjects. However, the authors themselves do not preclude the possibility 
that there could be a social influence on patients' behavior. Therefore, it 
would be convenient to join the biological with the cultural component. 
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This solution is indeed the most balanced answer to the question and the 
most appropriate to the characteristics of human personality. 
But the Kramer approach gives rise to several problems. How can 
we distinguish between the biological and the social? Can we compare the 
improvement obtained through the introduction of a pill with the long and 
accurate personal approach of a patient working with the help of a 
psychotherapist? Because Prozac is an anti-depressant, and two-thirds of 
depressed people are women, do we not run the risk of enforcing women's 
aggression and self-ambition skill levels, which are typical to the male 
gender and necessary in a postindustrial, service-oriented economy? 
This question leads us to reconsider the problem of assigning a 
growth hormone to short children with normal hormonal levels 
(constitutional shortness). Can we consider shyness, in the Prozac case, 
and shortness, in this second case, as diseases? 
A reply to the question is still awaited. The point is: although 
"pharmacological Calvinism" is to be rejected in total , whereas 
psychotherapy is to be viewed as the most helpful treatment for minor 
depression and anxiety, medication can speed treatment and engender self-
transformation on its own.s As a consequence, it is necessary to keep an 
open mind while critically evaluating the issue of cosmetic pharmacology, 
specifically when addressing patients' requests. 
Another Point of View 
We believe Sperry and Person's view is not the right one. As a matter 
of fact, the point should be: What usually justifies a specific medical act? 
The answer is and can only be: the presence of a pathology and the 
expectation of curing it, when no other intervention is possible. Thus, we 
totally agree with the assignment of a selective serotonin reuptake inhibitor 
to patients suffering from clinical mental disease or distress . We cannot 
justify its use in the absence of clinical disease or distress, for the purpose 
of enhancing performance. 
Quite obviously, it could be objected that since we are speaking of a 
drug which, according to our present knowledge, does not have side effects 
and makes the patient feel better, that its hedonistic use should also be 
acceptable. However, it is also true that an increase of serotonin level in the 
brain, responsible for performance enhancement, can be attained through 
such natural methods as increasing essential fats in one's diet, exercise, or 
even restful, restorative sleep, all without any medication. In addition, we 
should ask ourselves whether the use of a selective serotonin reuptake 
inhibitor does not cover over, once more, the real causes of disease such as 
personal and/or familiar dissatisfaction, therefore fulfills the needs induced 
by mass media influence, social permissivism, and industry or business. 
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Our perspective is not a "pharmacological Calvinism", because the 
opposition to the progressive dependence on medication does not originate 
from a condemnation of any pleasure (some pleasures are not symptoms of 
disorder), but from the observation that pleasure is healthy and constructive 
if it refers to the person's values and goes with the normal, not artificially 
produced, development of human personality. 
Physicians, and especially psychiatrists, have a particular 
responsibility for preventing this increasing pharmacological dependence. 
They have to see it as their precise duty to refuse any connivance and 
complicity either to patients' requests or to industrial profit. In addition, 
the whole of society must reflect upon the origins of human dissatisfaction 
(affective conflicts within families, social and environmental obstacles, 
lack of values, etc.), instead of quietly accepting artificial remedies that 
actually conceal social inefficiency. 
In conclusion, we can say that real prevention proceeds from 
commitment to education, to life and health values, and from the 
responsibility to ourselves and to others. The responsibility to others is 
crucial, since we must not forget that the more we spend on voluptuary 
pharmacology, the less we have at our disposal for real therapies directed 
to sick people who do require them. 
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